Home > Insider Trading > Filing (0000903423-19-000266)

Filing Details

Accession Number:: 0000903423-19-000266
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-06-28 19:02:51
Reporting Period:: 2019-06-27

Accepted Time:: 2019-06-28 19:02:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1743881	Bridgebio Pharma Inc.	BBIO	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1132625	Viking Global Performance Llc	55 Railroad Avenue Greenwich CT 06830	No	No	Yes	No
1133006	Andreas Ole Halvorsen	55 Railroad Avenue Greenwich CT 06830	No	No	Yes	No
1621596	Ltd. Master Fund Long Viking	55 Railroad Avenue Greenwich CT 06830	No	No	Yes	No
1621607	Viking Long Fund Gp Llc	55 Railroad Avenue Greenwich CT 06830	No	No	Yes	No
1621842	C. David Ott	55 Railroad Avenue Greenwich CT 06830	No	No	Yes	No
1711393	Sharon Rose Shabet	55 Railroad Avenue Greenwich CT 06830	No	No	Yes	No
1759530	Ltd. Master Equities Global Viking	55 Railroad Avenue Greenwich CT 06830	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-06-27	11,736,137	$0.00	11,736,137	No	4	C	Indirect	See Explanation of Responses
Common Stock	Acquisiton	2019-06-27	10,178,954	$0.00	21,915,091	No	4	C	Indirect	See Explanation of Responses
Common Stock	Acquisiton	2019-06-27	4,705,900	$17.00	26,620,991	No	4	P	Indirect	See Explanation of Responses

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Explanation of Responses
No	4	C	Indirect	See Explanation of Responses
No	4	P	Indirect	See Explanation of Responses

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Preferred Units	Disposition	2019-06-27	51,781,276	$0.00	11,736,137	$0.00
Common Stock	Series D Preferred Units	Disposition	2019-06-27	50,446,451	$0.00	10,178,954	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7.
O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Long Fund GP LLC ("VLFGP") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund Master Ltd. ("VLFM") and Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund," and together with VLFM and VGEM, the "Viking Funds").
VGP serves as the investment manager of VGEM. Opportunities Portfolio GP is the general partner of Opportunities Fund. VLFGP serves as the investment manager of VLFM. Each of the Viking Funds, VGI, VGP, VLFGP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively, the "Reporting Persons") may be deemed to beneficially own the shares reported on this form.
VGEM directly holds 631,167 shares of Common Stock; VLFM directly holds 251,204 shares of Common Stock; and Opportunities Fund directly holds 25,738,620 shares of Common Stock.
VGI provides managerial services to the Viking Funds. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares directly held by the Viking Funds. VGP is the investment manager of VGEM. Because of the relationships between VGP and VGEM, VGP may be deemed to beneficially own the shares directly held by VGEM. VLFGP serves as the investment manager of VLFM. Because of the relationship between VLFGP and VLFM, VLFGP may be deemed to beneficially own the shares directly held by VLFM.
Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Opportunities Fund.
The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
On June 27, 2019, the Viking Funds acquired an aggregate of 4,705,900 shares of Common Stock at a price of $17.00 per share in connection with the IPO. VGEM acquired 631,167 shares in the IPO, VLFM acquired 251,204 shares in the IPO and Opportunities Fund acquired 3,823,529 shares in the IPO.